Chronic myeloid leukemia, also known as chronic myelogenous leukemia or chronic granulocytic leukemia, is a cancer of the white blood cells characterized by the increased and unregulated growth of myeloid cells in the bone marrow and their accumulation in the blood. It is associated with the Philadelphia chromosome, a characteristic chromosomal translocation, and tyrosine-kinase inhibitors have dramatically improved survival rates since 2001; in Western countries it accounts for 15 to 25 percent of adult leukemias, and there were about 298,000 cases and 32,200 deaths worldwide in 2015.
Facts
Classification
Body SystemSourced to the subject's own accountLymphatic or Immune System 1 ICD-10 Chapter Communicable or Non-communicable Transmission Route Chronic Myeloid Leukemia
Filter Results1 entry
Connections
Treated By
Source Bcr-Abl tyrosine-kinase inhibitor (Wikipedia)
Sources
1. Chronic myelogenous leukemia (Wikipedia)
WikipediaInfobox: fieldQuote, Infobox: field
Haematology and oncology
View the Source 2. Wikipedia: ICD-10
WikipediaList of chapters, Chapter IIQuote, List of chapters, Chapter II
Neoplasms
View the Source 3. World Health Organization: Noncommunicable diseases (fact sheet)
World Health OrganizationLead section, transmission-route statement (inferred from disease-category)
The main types of NCDs are cardiovascular diseases (such as heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma) and diabetes.
Main Types section
The main types of NCDs are cardiovascular diseases (such as heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma) and diabetes.
View the Source Bcr-Abl tyrosine-kinase inhibitor (Wikipedia)
Treated By: Bcr-Abl Tyrosine-Kinase Inhibitor, Lead (321197)Quote, Treated By: Bcr-Abl Tyrosine-Kinase Inhibitor, Lead (321197)
Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML).
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.